Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 8.01 (Other Events). Cardiff sued Nerviano Medical Sciences in U.S. District Court to preserve its onvansertib license agreement.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Cardiff sued Nerviano Medical Sciences in U.S. District Court to preserve its onvansertib license agreement
- Dispute centers on inventorship of U.S. Patent Nos. 12,144,813 and 12,263,173
- NMS alleges Cardiff materially breached by excluding an NMS employee as joint inventor
- Cardiff seeks injunctive relief and a declaration that no breach occurred
- Adverse resolution could threaten Cardiff’s rights under the onvansertib license agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.